Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Sep 14, 2014; 20(34): 12313-12321
Published online Sep 14, 2014. doi: 10.3748/wjg.v20.i34.12313
Published online Sep 14, 2014. doi: 10.3748/wjg.v20.i34.12313
Table 1 Baseline characteristics and methodological assessment of the included trials
Ref. | Year | Study location | Patient (M/F) | Luaren classfication | Antibody source | Definition ofβ-catenin expression1 | NOS | ||
Intestinal | Diffuse | Mixed | |||||||
Ayed-Guerfali et al[13] | 2013 | Tunisia | 80 (45/35) | 48 | 32 | Santa Cruz | Normal/abnormal expression | 7 | |
Sereno et al[19] | 2012 | Spain | 44 (33/11) | 22 | 13 | 9 | Transduction Laboratories | Normal/abnormal expression | 6 |
Hou et al[20] | 2012 | China | 158 (105/53) | Santa Cruz | Normal/abnormal expression | 6 | |||
Liu et al[22] | 2012 | China | 134 (90/44) | Santa Cruz | Nuclear expression | 5 | |||
Sun et al[21] | 2012 | China | 58 (49/9) | Santa Cruz | Normal/abnormal expression | 5 | |||
Ryu et al[23] | 2012 | South Korea | 276 (NA) | BD Biosciences | Normal/abnormal expression | 7 | |||
Retterspitz et al[24] | 2010 | Germany | 94 (46/48) | 0 | 88 | 6 | BD Transduction | Membranous expression | 8 |
Kim et al[25] | 2010 | South Korea | 117 (81/36) | 40 | 75 | 2 | BD Transduction | Nuclear expression | 8 |
Czyzewska et al[26] | 2010 | Poland | 91 (62/29) | 61 | 30 | 0 | Novocastra Laboratories Ltd | Membranous expression | 6 |
Zali et al[28] | 2009 | Iran | 56 (38/18) | 35 | 16 | 5 | Research Diagnostic | Normal/abnormal expression | 8 |
Kim et al[29] | 2009 | South Korea | 598 (396/202) | BD Biosciences | Nuclear expression | 6 | |||
Bazas et al[30] | 2008 | Ukraine | 150 (89/61) | 117 | 33 | 0 | Dako Cytomation | Cytoplasmic expression | 8 |
Koriyama et al[31] | 2007 | Japan | 149 (NA) | 99 | 50 | 0 | Transduction Laboratories | Normal/abnormal expression | 8 |
Jung et al[32] | 2007 | South Korea | 111 (NA) | 44 | 67 | 0 | Transduction Laboratories | Nuclear expression | 9 |
Nabais et al[33] | 2003 | Portugal | 97 (NA) | 28 | 51 | 18 | Transduction Laboratories | Nuclear and cytoplasmic expression | 7 |
Zhou et al[34] | 2002 | China | 163 (123/40) | 108 | 40 | 15 | Maxim Biotech Inc. | Normal/abnormal expression | 8 |
Woo et al[14] | 2001 | South Korea | 303 (205/98) | 116 | 158 | 29 | Transduction Laboratories | Membranous expression | 9 |
Shun et al[35] | 2001 | Taiwan | 53 (NA) | 30 | 23 | Transduction Laboratories | Normal/abnormal expression | 6 | |
Grabsch et al[36] | 2001 | Germany | 401 (NA) | 255 | 112 | 34 | Transduction Laboratories | Nuclear and cytoplasmic expression | 6 |
Joo et al[37] | 2000 | South Korea | 65 (38/27) | 28 | 25 | 12 | Zymed Laboratories | Normal/abnormal expression | 7 |
Karatzas et al[38] | 2000 | Greece | 36 (NA) | 24 | 12 | Transduction Laboratories | Normal/abnormal expression | 6 | |
Ohene-Abuakwa et al[39] | 2000 | United Kingdom | 41 (NA) | 28 | 7 | 6 | Transduction Laboratories | Normal/abnormal expression | 7 |
Ramesh et al[15] | 1999 | United Kingdom | 40 (NA) | Affinity Research Products Ltd | Normal/abnormal expression | 8 | |||
Jawhari et al[40] | 1997 | England | 89 (62/27) | 63 | 24 | 2 | Affinity Research Products Ltd | Normal/abnormal expression | 7 |
Table 2 Stratified analysis of pooled hazard ratios
Subgroup analysis | Studies (n) | Pooled HR (95%CI) | P value | Heterogeneity | ||
Fixed | Random | I2(%) | P value | |||
Definition | ||||||
Abnormal | 5 | 2.12 (1.31-3.42) | 0.002 | 48 | 0.10 | |
Nucleus accumulation | 5 | 1.66 (0.90-3.06) | 0.270 | 83 | < 0.0001 | |
Loss of membrane expression | 5 | 1.61 (0.88-2.96) | 0.0006 | 75 | 0.003 | |
Cytoplasmic expression | 2 | 1.52 (1.05-2.19) | 0.020 | 0 | 0.56 | |
Study location | ||||||
Asia | 9 | 1.86 (1.23-2.80) | < 0.0001 | 81 | < 0.00001 | |
Other regions | 6 | 1.70 (1.33-2.19) | < 0.0001 | 9 | 0.36 | |
No. of patients | ||||||
> 100 | 9 | 1.82 (1.26-2.64) | 0.002 | 81 | < 0.00001 | |
≤ 100 | 6 | 1.81 (1.31-2.49) | 0.0003 | 3 | 0.40 | |
Publication year | ||||||
> 2000 | 12 | 1.83 (1.33-2.52) | < 0.00001 | 76 | < 0.00001 | |
≤ 2000 | 3 | 2.07 (1.13-3.81) | 0.020 | 0 | 0.76 | |
Antibody source | ||||||
BD transduction | 3 | 1.73 (0.64-4.69) | 0.280 | 90 | < 0.0001 | |
Transduction lab | 3 | 2.36 (1.06-5.27) | 0.040 | 75 | 0.02 | |
Santa cruz | 3 | 1.53 (1.18-1.97) | 0.001 | 44 | 0.17 | |
Other labs | 6 | 1.75 (1.37-2.25) | < 0.00001 | 7 | 0.37 |
Table 3 Meta-analysis of β-catenin expression and clinicopathological features of gastric cancer
Clinicopathological features | Studies (n) | Cases | Pooled OR (95%CI) | P value | Heterogeneity | ||
Fixed | Random | I2(%) | P value | ||||
Lauren classification | 17 | 1793 | 1.98 (1.19-3.29) | 0.009 | 74 | < 0.00001 | |
TNM stage | 9 | 996 | 1.34 (0.96-1.86) | 0.080 | 44 | 0.090 | |
The depth of invasion | 10 | 1203 | 1.48 (0.94-2.33) | 0.090 | 55 | 0.020 | |
Lymph node metastasis | 16 | 2147 | 2.00 (1.44-2.77) | < 0.0001 | 44 | 0.040 | |
Distant metastasis | 4 | 258 | 2.69 (1.35-5.38) | 0.005 | 20 | 0.290 | |
Grade of differentiation | 12 | 1372 | 2.68 (1.66-4.34) | 0.0002 | 58 | 0.006 | |
Vascular invasion | 3 | 774 | 1.11 (0.70-1.76) | 0.660 | 0 | 0.440 |
- Citation: Li LF, Wei ZJ, Sun H, Jiang B. Abnormal β-catenin immunohistochemical expression as a prognostic factor in gastric cancer: A meta-analysis. World J Gastroenterol 2014; 20(34): 12313-12321
- URL: https://www.wjgnet.com/1007-9327/full/v20/i34/12313.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i34.12313